February 23rd 2023
February 23rd 2023
Phase 3 CheckMate-227 Trial Met Co-Primary Endpoint of PFS in NSCLC
February 9th 2018This week, drug maker Bristol-Myers Squibb announced in a press release that the ongoing Phase 3 Checkmate-227 trial met its co-primary endpoint of progression-free survival with Opdivo plus Yervoy combination versus chemotherapy in first-line advanced non-small cell lung cancer patients whose tumors have high levels of an emerging biomarker called tumor mutation burden.
Read More
Adhering to Heart Failure Treatment Guidelines More Important Than Volume, Study Finds
February 7th 2018A recent study appearing in the American Heart Association journal Circulation, found that looking at how well hospitals adhere to treatment guidelines for heart failure is more important than comparing patient volumes at hospitals.
Read More
Dr Adam Brufsky: Choosing a Therapy for Breast Cancer Patients
February 4th 2018There are a number of treatment choices available to treat patients with breast cancer and diagnostic tests can assist in the decision making, according to Adam M. Brufsky, MD, PhD, co-director of the Comprehensive Breast Cancer Center at University of Pittsburgh.
Watch
Catheter Ablation More Effective Than Traditional Therapy in Atrial Fibrillation
February 3rd 2018A new study published in the February issue of the New England Journal of Medicine found that patients that received radiofrequency catheter ablation compared with traditional drug therapies for atrial fibrillation (AF) had significantly lower hospitalization and mortality rates.
Read More
Study Shows Interactive Tool Increases Patient Knowledge of Breast Cancer Treatment Options
January 31st 2018The Cancer Surveillance and Outcomes Research Team at the University of Michigan Comprehensive Cancer Center recently developed an interactive online tool to help patients with breast cancer understand their treatment options more fully.
Read More
New Guidelines for Rare Disease Advocacy Groups to Navigate Interactions With Pharma
January 28th 2018Only 5% of rare diseases have treatments, but approximately half have patient advocacy organizations; these groups have the potential to play major roles in positively influencing research and development of drugs, clinical trials, and regulations by championing funding and awareness efforts, forming connections between experts and drug developers, advocating for changes to regulation to expedite research, facilitating patient registries, or other initiatives.
Read More
Study to Determine Accuracy of Stool Tests for Colorectal Cancer
January 27th 2018The gold standard test for colon cancer detection is for patients to undergo a colonoscopy. However, the development of the fecal immunochemical test (FIT) provides patients with a noninvasive option that can be completed at home and would allow patients to forego the colonoscopy, if results are negative.
Read More
Treating Patients With Melanoma With Targeted Therapies Before Surgery Can Delay Relapse
January 20th 2018Researchers at The University of Texas MD Anderson Cancer Center recently reported in Lancet Oncology that a pair of targeted therapies given before and after surgery for melanoma produced a 6-fold increase in time to progression of the disease, compared with standard-of-care surgery for patients with stage 3 melanoma.
Read More
Risk-Targeted Lung Cancer Screening Shows Modest Benefits
January 19th 2018Although risk targeting may improve screening efficiency in terms of early lung cancer mortality per person screened, the gains in efficiency are modest in terms of life-years, quality-adjusted life-years, and cost-effectiveness, according to a study recently published in Annals of Internal Medicine.
Read More
AstraZeneca's Osimertinib on Track for First-Line Treatment of NSCLC With a Specific Mutation
January 11th 2018AstraZeneca’s epidermal growth factor receptor (EGFR) inhibitor, osimertinib (Tagrisso), is on the fast track in 2018 to become a first-line treatment for adult patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR mutations.
Read More
Combination Therapy May Benefit Subset of Patients With CLL Who Have Poor Response to Ibrutinib
January 7th 2018A subset of patients with chronic lymphocytic leukemia (CLL) with highly expressed CD49d have poorer outcomes while on Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, which antagonizes B-cell receptor (BCR) signals. However, a team of researchers may have found a way to treat these patients.
Read More
How Value Frameworks Define Durable Survival of New Immuno-Oncology Agents
January 1st 2018New immuno-oncology agents are providing durable survival for some patients, but the cost of these treatments is very high, which is a cause for concern. In a new study in JAMA Oncology, researchers sought to assess how value frameworks defined the efficacy of new immuno-oncology agents.
Read More